EdwardFoxMD

PubMed

• 1 citations
  Serum Neurofilament Light Trajectories and Their Relation to Subclinical Radiological Disease Activity in Relapsing Multiple Sclerosis Patients in the APLIOS Trial.
  Amit Bar-Or, Xavier Montalban, Xixi Hu, Harald Kropshofer, Petra Kukkaro, Neva Coello, Inga Ludwig, Roman Willi, Martin Zalesak, Krishnan Ramanathan, Bernd C Kieseier,...> ;Neurology and Therapy. 2023 Feb 1
• 2 citations
  Working to Increase Stability through Exercise (WISE): screening, recruitment, and baseline characteristics
  Christopher N. Sciamanna, Noel H. Ballentine, Melissa Bopp, Vernon M. Chinchilli, Joseph T. Ciccolo, Gabrielle Delauter, Abigail Fisher, Edward Fox, Suzanne M. Jan de ...> ;Trials. 2021 Nov 15
• 26 citations
  Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study
  Amit Bar-Or, Heinz Wiendl, Xavier Montalban, Enrique Alvarez, M. V. Davydovskaya, Silvia Delgado, E. P. Evdoshenko, Natasa Giedraitiene, Katrin Gross-Paju, Sulev Haldr...> ;Multiple Sclerosis. 2021 Oct 4
• 19 citations
  Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis
  Amit Bar-Or, Susan O'Brien, Michael Sweeney, Edward Fox, Jeffrey A. Cohen> ;CNS Drugs. 2021 Aug 9
• 9 citations
  B cell depletion changes the immune cell profile in multiple sclerosis patients: One-year report.
  Amy E. Lovett-Racke, Yuhong Yang, Yue Liu, Matthew Gormley, Emma E. Kraus, Calsey Graham, Sibyl Wray, Michael K. Racke, Enrique Alvarez, Ann D Bass, Edward Fox> ;Journal of Neuroimmunology. 2021 Oct 15
• 9 citations
  Novel fusion sarcomas including targetable NTRK and ALK.
  Tiane Chen, Ying Wang, Lianna Goetz, Zachary Corey, Meaghan C. Dougher, Jessica D. Smith, Edward Fox, Andrew S. Freiberg, Donald J. Flemming, Julie C. Fanburg-Smith> ;Annals of Diagnostic Pathology. 2021 Jul 22
• Spontaneous Hip Dislocation Complicating the Management of Malignant Peripheral Nerve Sheath Tumor Arising Within a Plexiform Neurofibroma.
  Oliver D. Mrowczynski, Monali Vasekar, Edward Fox, Kimberly Harbaugh, Dawit Aregawi, Colette R. Pameijer, Nicholas G. Zaorsky, Russell Payne, Elias Rizk> ;Cureus. 2021 Jul 11
• 5 citations
  Lymphocyte counts and infection rates: Long-term fingolimod treatment in primary progressive MS
  Edward Fox, Fred D. Lublin, Jerry S. Wolinsky, Jeffrey A. Cohen, Ian M. Williams, Xiangyi Meng, Marina Ziehn, Scott Kolodny, Bruce A.C. Cree> ;Neurology(R) Neuroimmunology & Neuroinflammation. 2019 Nov 1
• Identifiability and estimation of structural vector autoregressive models for subsampled and mixed-frequency time series.
  Tank, A.,Fox, E. B.,Shojaie, A.> ;Biometrika. 2019 May 18
• Real-world durability of relapse rate reduction in patients with multiple sclerosis receiving fingolimod for up to 3 years: a retrospective US claims database analysis.
  Fox, E.,Vieira, M. C.,Johnson, K.,Peeples, M.,Bensimon, A. G.,Signorovitch, J.,Herrera, V.> ;J. Neurol. Sci.. 1900 Jan 01
• A young man with numbness in arms and legs: From the National Multiple Sclerosis Society Case Conference Proceedings.
  Romeo, A. R.,Lisak, R. P.,Meltzer, E.,Fox, E. J.,Melamed, E.,Lucas, A.,Freeman, L.,Frohman, T. C.,Costello, K.,Zamvil, S. S.,Frohman, E. M.,Gelfand, J. M.> ;Neurol Neuroimmunol Neuroinflamm. 2018 Nov 23
• Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO ...
  Fox, E. J.,Markowitz, C.,Applebee, A.,Montalban, X.,Wolinsky, J. S.,Belachew, S.,Fiore, D.,Pei, J.,Musch, B.,Giovannoni, G.> ;Mult. Scler.. 2018 Nov 13
• The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.
  Kappos L, Edan G, Freedman MS, Montalbán X, Hartung H, Hemmer B, Fox EJ, Barkhof F, Schippling S, Schulze A, Pleimes D, Pohl C, Sandbrink R, Suarez G, Wicklein E> ;Neurology. 2016-09-06
• 15 citations
  Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients.
  Edward Fox, Daniel Wynn, Alasdair Coles, Jeffrey Palmer, David Margolin> ;Journal of the Neurological Sciences. 2016 Apr 15
• Gastrointestinal Tolerability of Delayed-Release Dimethyl Fumarate in a Multicenter, Open-Label Study of Patients with Relapsing Forms of Multiple Sclerosis (MANAGE).
  Fox EJ, Vasquez A, Grainger W, Ma TS, von Hehn C, Walsh J, Li J, Zambrano J> ;Int J MS Care. 2016-01-01
• Effects of functional electrical stimulation on gait function and quality of life for people with multiple sclerosis taking dalfampridine.
  Mayer L, Warring T, Agrella S, Rogers HL, Fox EJ> ;Int J MS Care. 2015-01-01
• 65 citations
  Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study...
  Edward Fox, Keith R. Edwards, Gordon Burch, Daniel Wynn, Chris LaGanke, Heidi Crayton, Samuel F. Hunter, Cynthia Huffman, Edward Kim, Linda Pestreich, Kevin McCague, L...> ;Multiple Sclerosis and Related Disorders. 2014 Sep 1
• 5 citations
  Risks of double-counting in deep sequencing.
  Michael W. Schmitt, Edward J. Fox, Jesse J. Salk> ;Proceedings of the National Academy of Sciences of the United States of America. 2014 Apr 22
• 1 citations
  The effect of scheduled antibody testing on treatment patterns in interferon-treated patients with multiple sclerosis
  Edward Fox, Barbara Green, Clyde E. Markowitz, Ronald Murray, Andrew D. Goodman, Stephen J Glenski, Pippa Loupe, Jo Nita Cogburn> ;BMC Neurology. 2014 Apr 4
• 660 citations
  Detection of ultra-rare mutations by next-generation sequencing
  Michael W. Schmitt, Scott R. Kennedy, Jesse J. Salk, Edward J. Fox, Joseph Hiatt, Lawrence A. Loeb> ;Proceedings of the National Academy of Sciences of the United States of America. 2012 Sep 4
• Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial.
  Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Skoromets A, Stolyarov I, Bass A, Sullivan H, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DAS> ;Neurology. 2012-04-03
• 39 citations
  New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis.
  Edward Fox, Robert W Rhoades> ;Current Opinion in Neurology. 2012 Jan 1
• 37 citations
  A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis
  Edward Fox, H. C. Sullivan, Suzanne Gazda, Lori Mayer, L. O'Donnell, K. Melia, Stephen Lake> ;European Journal of Neurology. 2012 Feb 1
• A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
  Cuker A, Coles AJ, Sullivan H, Fox E, Goldberg M, Oyuela P, Purvis A, Beardsley DS, Margolin DH> ;Blood. 2011-12-08
• An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjects.
  Phillips JT, Fox E, Grainger W, Tuccillo D, Liu S, Deykin A> ;BMC Neurol. 2011-10-14
• Join now to see all